How to Reconstitute Tirzepatide 30mg: The Complete Mixing Protocol for Compounded Peptides

Reviewed by FormBlends Medical Team · Last updated September 2026 · Sources listed below

Key Takeaways

• Reconstituting 30mg tirzepatide with 3mL bacteriostatic water creates a 10mg/mL solution, the most common concentration for clean unit-to-dose math on U-100 syringes
• The final concentration depends entirely on how much bacteriostatic water you add, not on the powder amount; 1.5mL creates 20mg/mL, 2mL creates 15mg/mL, 3mL creates 10mg/mL
• Use a reconstituted vial by the beyond-use date on the pharmacy label. USP <797> caps any multiple-dose sterile preparation at 28 days after first puncture, or the assigned beyond-use date if shorter; that 28-day figure is a regulatory limit, not a tirzepatide stability finding
• The single most common reconstitution error is injecting air bubbles into the powder vial before adding water, which creates foam that takes 20+ minutes to settle

The short answer

To reconstitute 30mg tirzepatide, inject 3mL of bacteriostatic water slowly down the inside wall of the vial, never directly onto the powder. Let it dissolve passively for 3-5 minutes without shaking. This creates a 10mg/mL solution where each 2.5mg dose equals 25 units on a U-100 insulin syringe. Refrigerate immediately after mixing.

To get the units for your own vial, use the tirzepatide dosage calculator. Enter the vial size, the water you add and your dose; it returns the draw in units and millilitres and shows which water volume lands your dose on a printed mark.

Table of contents

1. What reconstitution means and why compounded tirzepatide requires it
2. Materials checklist: everything you need before starting
3. The concentration decision: how much bacteriostatic water to add
4. Step-by-step reconstitution protocol with sterile technique
5. What most articles get wrong about the mixing process
6. Concentration math: converting your final solution to syringe units
7. The three failure modes of peptide reconstitution
8. Post-reconstitution storage, dating, and stability
9. Visual inspection: what properly reconstituted tirzepatide looks like
10. When reconstitution goes wrong: troubleshooting cloudiness, foam, and particles
11. The decision tree: should you reconstitute or order pre-mixed
12. How long it is good for: what USP <797> says
13. The dosing-error problem FDA has documented
14. Approved-label storage rules and why they do not transfer
15. FAQ
16. Sources

What reconstitution means and why compounded tirzepatide requires it

Reconstitution is the process of mixing a lyophilized (freeze-dried) powder medication with a sterile liquid to create an injectable solution. Compounded tirzepatide is shipped as a powder because peptides are more stable in solid form during shipping and storage. The powder form extends shelf life from weeks to months.

When you receive a vial labeled "tirzepatide 30mg for reconstitution," you're receiving pure tirzepatide powder (plus inactive stabilizers like mannitol or trehalose) in a vacuum-sealed sterile vial. The vial is not ready to inject. You add bacteriostatic water to dissolve the powder, creating the liquid solution you'll draw into a syringe.

The reconstitution step is identical to what hospitals do with powdered antibiotics, chemotherapy agents, and other peptide medications. It's not experimental or unusual. The difference is that you're doing it at home instead of a pharmacy tech doing it in a clean room.

Why compounding pharmacies ship powder instead of pre-mixed liquid:

• Stability. Store the unopened powder vial exactly as the pharmacy labels it; published stability data for compounded lyophilized tirzepatide do not exist, and each pharmacy's dating is its own. Once reconstituted, the vial must be refrigerated and used by the pharmacy's beyond-use date, which USP <797> caps at 28 days after first puncture. Shipping pre-mixed vials requires cold-chain logistics that not every pharmacy offers for residential delivery.
• Customization. Powder lets you control the final concentration by adjusting the volume of bacteriostatic water. A patient who needs very small doses (2.5mg) might prefer 5mg/mL for easier syringe reading. A patient at higher doses (15mg) might prefer 20mg/mL to reduce injection volume.
• Cost. Lyophilization equipment is cheaper than sterile liquid-fill lines. Most small compounding pharmacies have freeze-dryers but not the cleanroom infrastructure for large-scale liquid filling.

The tradeoff is that reconstitution adds a step. You become part of the compounding process. The pharmacy prepares the powder; you prepare the solution.

Materials checklist: everything you need before starting

Gather everything before you start. Reconstitution is a sterile procedure. Once you've opened the vials, you can't pause to hunt for supplies.

Required materials:

• Tirzepatide 30mg vial (lyophilized powder, sealed with a rubber stopper and flip-off cap)
• Bacteriostatic water for injection (typically a 10mL or 30mL vial, 0.9% benzyl alcohol as preservative)
• Two sterile syringes with needles. Most pharmacies include a 3mL or 5mL syringe with an 18-gauge or 20-gauge needle for reconstitution, plus a separate U-100 insulin syringe (0.3mL or 0.5mL barrel, 31-gauge needle) for dosing. If not included, buy them separately. Do not use the same syringe for both steps.
• Alcohol prep pads (at least four)
• Sharps container
• Permanent marker (to label the vial with reconstitution date and concentration)
• Clean, flat surface (kitchen counter wiped with disinfectant or a clean towel)

Optional but recommended:

• Sterile gloves (non-powdered nitrile)
• Gauze pads (if the rubber stopper bleeds small amounts of rubber particulate when punctured repeatedly)
• Timer (to track the 3-5 minute passive dissolution period)

Do not substitute tap water, sterile saline, or distilled water for bacteriostatic water. Bacteriostatic water contains 0.9% benzyl alcohol, which prevents bacterial growth in the vial over the 28-day use period. Sterile water without preservative is single-use only. Tap water is not sterile and will contaminate the vial.

The concentration decision: how much bacteriostatic water to add

The amount of bacteriostatic water you add determines the final concentration. The 30mg of tirzepatide powder is fixed. The volume is variable.

Standard reconstitution volumes for 30mg tirzepatide:

Bacteriostatic water added	Final concentration	2.5mg dose	5mg dose	7.5mg dose	10mg dose	12.5mg dose	15mg dose
1.5 mL	20 mg/mL	12.5 units	25 units	37.5 units	50 units	62.5 units	75 units
2.0 mL	15 mg/mL	17 units	33 units	50 units	67 units	83 units	100 units
3.0 mL	10 mg/mL	25 units	50 units	75 units	100 units	125 units	150 units
6.0 mL	5 mg/mL	50 units	100 units	150 units	200 units	250 units	300 units

The 3mL reconstitution (10mg/mL) is the most common because the math is clean. Every 1mg of tirzepatide equals 10 units on a U-100 syringe. A 2.5mg dose is 25 units, 5mg is 50 units, 7.5mg is 75 units. No fractions, no half-unit markings required.

The 1.5mL reconstitution (20mg/mL) is used when injection volume matters. Patients at high doses (12.5mg or 15mg) can reduce injection volume by half compared to 10mg/mL. The tradeoff is that low doses (2.5mg) become 12.5 units, which requires reading half-unit markings on the syringe.

The 6mL reconstitution (5mg/mL) is rarely used unless a patient is at very low doses (2.5mg) and has difficulty reading small unit counts. The 50-unit draw for 2.5mg is easier to see, but injection volume doubles.

The 2mL option (15mg/mL) suits patients at 10mg or higher who want smaller injection volumes but do not need the 20mg/mL concentration. Correction, September 2026: an earlier version of this paragraph cited FormBlends usage statistics for these options; those figures were not drawn from any verifiable dataset and have been removed.

How to decide:

• If you're starting at 2.5mg or 5mg and unsure how high you'll titrate, use 3mL. It works for every dose from 2.5mg to 15mg without requiring a syringe larger than 1mL.
• If you're already at 10mg or higher and injection volume bothers you, use 2mL.
• If you have difficulty reading small numbers on syringes, use 6mL for the first month, then switch to 3mL once you're comfortable with the process.

Your pharmacy's reconstitution instructions will specify a volume. You can deviate from it, but if you do, you must recalculate the unit count for every dose. Most dosing errors occur when patients mix at one concentration and dose using a chart for a different concentration.

Step-by-step reconstitution protocol with sterile technique

This protocol assumes you're reconstituting a 30mg vial with 3mL bacteriostatic water to create a 10mg/mL solution. Adjust the water volume for other concentrations.

Preparation (2 minutes):

1. Wash your hands with soap and water for 20 seconds. Dry with a clean towel.
2. Clean your work surface. Wipe with a disinfectant wipe or spray. Let it air-dry.
3. Remove the flip-off caps from both vials (tirzepatide and bacteriostatic water). The rubber stoppers underneath should be intact and free of cracks.
4. Wipe both rubber stoppers with separate alcohol pads. Let them air-dry for 10 seconds. Do not blow on them or touch them after wiping.
5. Inspect the tirzepatide powder. It should be a white to off-white solid cake at the bottom of the vial, sometimes with a slight yellowish tint. If it's discolored (gray, brown, pink), clumped with moisture, or the vial has visible cracks, do not use it. Contact the pharmacy.

Drawing bacteriostatic water (3 minutes):

1. Attach the 18-gauge or 20-gauge needle to the 3mL syringe. Keep the needle cap on.
2. Pull the syringe plunger back to draw 3mL of air into the barrel.
3. Remove the needle cap. Insert the needle through the rubber stopper of the bacteriostatic water vial. Push the 3mL of air into the vial. This equalizes pressure and makes it easier to draw liquid.
4. Invert the bacteriostatic water vial with the needle still inserted. Pull the plunger back slowly to draw 3mL of liquid. The meniscus (curved surface of the liquid) should sit exactly on the 3mL line when the syringe is held at eye level.
5. Check for air bubbles. If large bubbles are present, push the liquid back into the vial and re-draw. Small micro-bubbles (smaller than 1mm) are harmless.
6. Remove the needle from the bacteriostatic water vial. Do not recap the needle. Set the syringe down on a clean surface with the needle pointing up.

Reconstituting the tirzepatide powder (5 minutes):

1. Pick up the syringe. Insert the needle through the rubber stopper of the tirzepatide vial at a slight angle, aiming for the inside wall of the vial, not the center.
2. Inject the bacteriostatic water slowly down the inside wall of the vial. The water should run down the glass and pool at the bottom, gradually wetting the powder from the edges. Do not aim the stream directly at the powder cake. Direct injection creates foam and can denature the peptide.
3. Withdraw the needle. Do not shake, swirl, or invert the vial. Set it upright on the counter.
4. Wait 3 to 5 minutes. The powder will dissolve passively. You'll see the solid cake gradually disappear as the water saturates it. Gentle side-to-side tilting (not shaking) is acceptable after 2 minutes if some powder remains undissolved.
5. Inspect the solution. It should be clear and colorless to faint straw-yellow. No visible particles, no cloudiness, no foam on the surface. If foam is present, wait another 5 minutes for it to settle. If cloudiness persists after 10 minutes, do not use the vial.

Labeling and storage (1 minute):

1. Label the vial with a permanent marker. Write the reconstitution date, the concentration (10mg/mL), and the discard date (28 days from today). Example: "Reconstituted 4/29/26, 10mg/mL, Discard 5/27/26."
2. Refrigerate immediately. Store at 36-46°F (2-8°C). Do not freeze. Do not leave at room temperature for more than 2 hours.
3. Dispose of the reconstitution syringe and needle in a sharps container. Do not reuse.

The entire process takes 10-12 minutes the first time. By the third vial, most patients complete it in 6-7 minutes.

What most articles get wrong about the mixing process

The most common error in published reconstitution guides is the instruction to "inject the water directly into the powder" or "aim for the center of the vial." This creates foam.

Tirzepatide is a 39-amino-acid peptide with a hydrophobic fatty acid chain. When you inject water directly onto the powder at high velocity, you create turbulence. The peptide molecules at the air-water interface denature partially, forming a foam layer. The foam takes 15-30 minutes to settle, and some of the denatured peptide doesn't re-dissolve.

Correction, September 2026: an earlier version of this section cited a 2023 Journal of Pharmaceutical Sciences study by Larsen et al. with recovery figures of 91.3 and 98.7 percent. No such article could be found, and the figures have been removed. Injecting slowly down the vial wall and not shaking remain standard good practice in pharmacy reconstitution instructions; the size of any loss from foaming has not been quantified in a source we can cite.

The correct technique is to aim the needle at the inside wall of the vial, inject slowly (3mL over 15-20 seconds), and let the water run down the glass. The powder dissolves from the edges inward and little or no foam forms.

The second error is shaking the vial to speed dissolution. Shaking introduces air and creates the same foam problem. Peptides dissolve in water passively. Tirzepatide powder fully dissolves in 3-5 minutes without agitation. If you're impatient, gentle side-to-side tilting (not shaking) after 2 minutes is acceptable, but it doesn't meaningfully speed the process.

The third error is using a needle that's too small (25-gauge or smaller) for reconstitution. Small-gauge needles create high back-pressure when you push the plunger, which increases the velocity of the water stream when it exits the needle. Use an 18-gauge or 20-gauge needle for reconstitution. Save the 31-gauge needles for injection.

Concentration math: converting your final solution to syringe units

Once you've reconstituted, the concentration is fixed. The math to convert milligram doses to syringe units is:

(Dose in mg ÷ Concentration in mg/mL) × 100 = Units on a U-100 syringe

Example: you want to inject 5mg. Your vial is 10mg/mL.

(5 ÷ 10) × 100 = 50 units

If your vial is 20mg/mL:

(5 ÷ 20) × 100 = 25 units

The "× 100" step converts milliliters to units. A U-100 syringe has 100 units per mL. So 0.5mL = 50 units, 0.25mL = 25 units, 1.0mL = 100 units.

Quick reference for 10mg/mL (30mg powder + 3mL water):

• 2.5mg = 25 units (0.25mL)
• 5mg = 50 units (0.5mL)
• 7.5mg = 75 units (0.75mL)
• 10mg = 100 units (1.0mL)
• 12.5mg = 125 units (1.25mL)
• 15mg = 150 units (1.5mL)

Quick reference for 20mg/mL (30mg powder + 1.5mL water):

• 2.5mg = 12.5 units (0.125mL)
• 5mg = 25 units (0.25mL)
• 7.5mg = 37.5 units (0.375mL)
• 10mg = 50 units (0.5mL)
• 12.5mg = 62.5 units (0.625mL)
• 15mg = 75 units (0.75mL)

Write the unit count for your prescribed dose on the vial label in marker. You should not have to recalculate every week. Calculate once, write it down, refer to it.

If your dose changes mid-vial (e.g., your provider increases you from 5mg to 7.5mg), recalculate and update the label. Cross out the old unit count, write the new one. Do not rely on memory.

The three failure modes of peptide reconstitution

Reconstitution can fail in three ways. Each has a different root cause and a different fix.

Failure Mode 1: Incomplete dissolution (visible powder remains after 10 minutes).

Cause: The powder cake is too dense, the water didn't penetrate evenly, or the vial was stored in a freezer before reconstitution (which can cause the powder to clump).

Fix: Tilt the vial gently side-to-side for 30 seconds. Do not shake. Wait another 5 minutes. If powder still remains, the vial is unusable. Tirzepatide should dissolve completely in bacteriostatic water. Persistent undissolved powder suggests degradation or contamination during lyophilization.

Prevention: Store powder vials at room temperature or refrigerated, never frozen. Inspect the powder before reconstitution. If it's clumped or stuck to the side of the vial instead of settled at the bottom, it may have been temperature-cycled during shipping.

Failure Mode 2: Cloudiness or precipitate formation.

Cause: The peptide aggregated because of contamination, degradation before mixing, or exposure to heat or light. Cloudiness usually means the powder was compromised before reconstitution or the bacteriostatic water was contaminated. (A pH range for tirzepatide that appeared here earlier was unsourced and has been removed.)

Fix: Do not use a cloudy solution. Cloudiness indicates aggregated peptide, which is less effective and potentially immunogenic. Contact the pharmacy for a replacement vial.

Prevention: Use bacteriostatic water from a sealed, sterile vial. Do not use water from a vial that's been open for more than 28 days. Store the tirzepatide powder vial in its original box to protect it from light.

Failure Mode 3: Foam that doesn't settle.

Cause: You injected the water too fast, aimed directly at the powder, or shook the vial. Foam is denatured peptide at the air-water interface.

Fix: Wait 20-30 minutes; most foam settles. If foam persists, contact the pharmacy before using the vial. No published data quantify how much peptide is lost to foaming, so do not assume a particular potency.

Prevention: Inject water slowly down the vial wall. Never shake. Use an 18-gauge or 20-gauge needle for reconstitution to reduce injection velocity.

[Diagram suggestion: three-panel illustration showing each failure mode with a labeled vial, a red X, and a one-sentence caption explaining the visual cue that indicates failure]

Post-reconstitution storage, dating, and stability

Once reconstituted, use the vial by the beyond-use date on the pharmacy label and keep it refrigerated at 36-46°F (2-8°C). USP <797> (revision official November 1, 2023) does not publish a peptide stability window; it sets beyond-use dates by preparation category and caps any multiple-dose container at 28 days after first puncture or the assigned date, whichever is shorter. Correction, September 2026: an earlier version described 28 days as a USP stability finding for reconstituted peptides; that was inaccurate.

Temperature rules:

• Refrigerate immediately after reconstitution. Do not leave at room temperature for more than 2 hours.
• Do not freeze. Freezing causes ice crystal formation, which disrupts the peptide structure. A frozen vial is unusable.
• Avoid temperature cycling. Repeated warming and cooling is bad practice for any peptide solution. If you're traveling, use an insulated bag with a gel pack (not direct ice). Follow the pharmacy label for any room-temperature allowance; the approved Zepbound and Mounjaro labels allow up to 21 days at up to 30 C for their own pens and vials (revised 08/2026), but that data does not transfer to a compounded vial.

Dating:

Write the discard date on the vial label the day you reconstitute. Count 28 days forward. Example: reconstituted April 29, discard May 27. Do not use the vial after the discard date even if solution remains.

Some pharmacies assign a shorter beyond-use date than 28 days, based on their own preparation category and testing. USP <797> requires the shorter of the assigned date or 28 days after first puncture, so the pharmacy's date always governs.

Light exposure:

Protect the vial from light. The approved tirzepatide labels say to store the product in the original carton to protect it from light (Zepbound and Mounjaro, revised 08/2026); keep a compounded vial in its box for the same reason. Correction, September 2026: a 48-to-72-hour sunlight degradation figure that appeared here had no source and has been removed.

Stability data:

Correction, September 2026: an earlier version of this page cited a 2024 Pharmaceutical Research study by Chen et al. with potency figures at 4 C and 25 C over 56 days. No such article could be found, and every potency percentage has been removed. No published stability study of reconstituted compounded tirzepatide exists that we can cite. The governing facts are the pharmacy's beyond-use date and the USP <797> 28-day multiple-dose cap.

Visual inspection: what properly reconstituted tirzepatide looks like

Before every injection, inspect the solution. Reconstituted tirzepatide should be:

• Clear. You should be able to read text through the vial. No haze, no cloudiness.
• Colorless to faint straw-yellow. A slight yellow tint is normal and comes from oxidation of trace impurities during lyophilization. Deep yellow, orange, pink, or red is abnormal.
• Particle-free. No floating specks, no settled sediment at the bottom, no fibers. Hold the vial up to a light and rotate it slowly. Particles are easier to see against a bright background.

Color variations and what they mean:

• Clear and colorless: normal.
• Faint straw-yellow: normal. This is the most common appearance after 7-14 days of refrigerated storage.
• Pink or red: the pharmacy added cyanocobalamin (vitamin B12). Some compounding pharmacies include B12 in tirzepatide formulations. If you didn't expect color and the vial label doesn't mention B12, call the pharmacy.
• Orange or brown: oxidation or degradation. Do not use.
• Cloudy or milky: aggregation. Do not use.

If you're unsure whether a color change is normal, take a photo and text it to the pharmacy. Most compounding pharmacies have a clinical line that responds within 2-4 hours.

When reconstitution goes wrong: troubleshooting cloudiness, foam, and particles

Problem: The solution is cloudy immediately after reconstitution.

Likely cause: The bacteriostatic water was contaminated, the powder was degraded before reconstitution, or the water and powder are incompatible (wrong pH, wrong ionic strength).

Action: Do not use. Contact the pharmacy for a replacement. Cloudiness at the time of reconstitution is a sterility or formulation issue, not a user error.

Problem: The solution was clear at reconstitution but turned cloudy after 3-7 days in the refrigerator.

Likely cause: Peptide aggregation due to temperature cycling, light exposure, or bacterial contamination.

Action: Do not use. Aggregated peptide is less effective and can trigger immune responses. Dispose of the vial. If this happens with a second vial, the issue is likely storage conditions (refrigerator too warm, door opened frequently, vial exposed to light). Use a refrigerator thermometer to confirm 36-46°F.

Problem: Foam formed during reconstitution and won't settle after 30 minutes.

Likely cause: You injected the water too fast or shook the vial.

Action: Contact the pharmacy before using it; no published data quantify potency loss from foaming. To prevent foam in future reconstitutions, inject water slowly (3mL over 15-20 seconds) and aim for the vial wall, not the powder.

Problem: Small particles (white specks, fibers) are visible when you hold the vial up to light.

Likely cause: Rubber stopper particulate (small pieces of the rubber stopper sheared off when you punctured it with the needle) or glass fragments (rare, but possible if the vial was cracked).

Action: Do not use. Injecting particulate matter can cause injection-site reactions or, in rare cases, embolism. Contact the pharmacy for a replacement. To reduce rubber particulate in future vials, use a larger-gauge needle (18-gauge) for reconstitution and puncture the stopper in the center, not near the edge.

Problem: The powder didn't fully dissolve, and small clumps remain at the bottom after 10 minutes.

Likely cause: The powder was stored frozen or temperature-cycled before reconstitution, causing it to clump.

Action: Tilt the vial gently side-to-side for 30 seconds. Wait another 5 minutes. If clumps persist, do not use. Undissolved powder means you can't accurately measure the dose. Contact the pharmacy.

The decision tree: should you reconstitute or order pre-mixed

Not every patient should reconstitute. Pre-mixed vials are available from some compounding pharmacies at a higher cost. The decision depends on four factors: cost sensitivity, comfort with sterile technique, dose stability, and shipping logistics.

You should reconstitute if:

• You're cost-sensitive. Powder vials are often priced below pre-mixed vials because they avoid cold-chain shipping; compare dated cash prices by provider in the Compounded GLP-1 Price Index.
• You want control over concentration. Reconstituting lets you customize the concentration to match your dose range and syringe preference.
• You're comfortable with multi-step procedures. If you've mixed medications before (e.g., insulin, antibiotics for a child), reconstitution is straightforward.
• You have reliable refrigeration. Reconstituted vials must be refrigerated continuously. If you travel frequently or live in a setting where power outages are common, powder vials (which are stable at room temperature before reconstitution) give you more flexibility.

You should order pre-mixed if:

• You're not comfortable with sterile technique. Reconstitution requires attention to detail. If you're anxious about contamination or making a mistake, pre-mixed vials eliminate the risk.
• You're at a stable dose and don't need concentration flexibility. If you've been at 5mg for 12 weeks and don't plan to titrate, a pre-mixed 10mg/mL vial works fine.
• You value convenience over cost. Pre-mixed vials are ready to use. No setup, no waiting, no supplies to manage.
• Your pharmacy offers cold-chain shipping. Not all compounding pharmacies can ship refrigerated vials. If yours can, pre-mixed is an option. If not, powder is your only choice.

Whichever you start with, the choice tends to stick, so it is worth deciding deliberately. Correction, September 2026: switching percentages that appeared here were not drawn from any verifiable dataset and have been removed.

When you should NOT reconstitute:

• You have a tremor or motor control issue that makes precise needle work difficult.
• You have severe vision impairment and can't read syringe markings clearly.
• You're in a living situation where you can't guarantee sterile conditions (e.g., shared housing with limited access to clean surfaces).
• You have a needle phobia severe enough that the reconstitution process (which requires handling needles and vials) triggers anxiety.

In these cases, pre-mixed vials or switching to a brand-name pen (if insurance covers it) is the better choice.

How long reconstituted tirzepatide is good for: what USP <797> actually says

The 28-day figure that circulates online is a regulatory cap, not a measurement of tirzepatide. USP General Chapter <797>, the sterile compounding standard that state boards enforce (revision official November 1, 2023), says a multiple-dose compounded sterile preparation may not be used beyond its assigned beyond-use date or 28 days after it is first punctured, whichever is shorter. The beyond-use date itself depends on how the pharmacy made and tested the preparation:

USP <797> category (2023 revision)	Room temperature	Refrigerated (2 to 8 C)	Frozen
Category 1	12 hours or less	24 hours or less	not applicable
Category 2, aseptically processed from sterile components, no sterility test	4 days	10 days	45 days
Category 2, aseptically processed, sterility tested	30 days	45 days	60 days
Category 2, terminally sterilized, no sterility test	14 days	28 days	45 days
Category 2, terminally sterilized, sterility tested	45 days	60 days	90 days
Category 3 (extended testing)	up to 60 or 90 days	up to 90 or 120 days	up to 120 or 180 days
Any multiple-dose container, after first puncture	Not used beyond the assigned beyond-use date or 28 days, whichever is shorter

What this means for you: the date on your pharmacy label already reflects the pharmacy's category and testing, and it is the only number that governs. If the label says 21 days, 21 days it is. No published study measures the potency of reconstituted compounded tirzepatide over time, so any percentage you read (including ones that appeared on earlier versions of this page) is not evidence.

Sources: Florida Department of Health, USP <797> inspection form, August 2024; Mississippi Board of Pharmacy, USP compounding BUD fact sheet.

The dosing-error problem FDA has documented

The reason the unit math on this page matters is written down by FDA. Its July 26, 2024 alert on compounded GLP-1 products described patients who were told to draw, for example, 5 units (0.05 mL) and instead drew 50 units, giving themselves 5 to 20 times the intended dose, and clinicians who miscalculated milligram-to-unit conversions by 5 to 10 times. Reported effects included nausea, vomiting, abdominal pain, fainting, headache, migraine, dehydration, acute pancreatitis and gallstones, and some patients were hospitalized. FDA's page on unapproved GLP-1 drugs (content current as of September 1, 2026) reports more than 730 adverse-event reports for compounded tirzepatide and 990 for compounded semaglutide as of May 31, 2026, notes that compounding pharmacies are not required to report, and lists dosing errors by patients and clinicians among the causes. The same page records that FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage on February 21, 2025.

Practical rule: calculate units once with the formula above or the tirzepatide dosage calculator, write the result on the vial, and have your pharmacy confirm it. Never convert in your head at injection time.

Sources: FDA dosing-error alert, July 26, 2024; FDA, concerns with unapproved GLP-1 drugs.

Storage rules from the approved tirzepatide labels (August 2026) and why they do not transfer to compounded vials

The Zepbound and Mounjaro prescribing information, both revised 08/2026, are the only FDA-reviewed storage data for tirzepatide. Section 16 says: refrigerate at 2 to 8 C (36 to 46 F); do not freeze and do not use if frozen; store in the original carton to protect from light; a single-dose pen or vial may be kept unrefrigerated at up to 30 C (86 F) for a total of 21 days, then discarded; the multi-dose vial and single-patient-use KwikPen have their own in-use limits.

Those figures were generated for Lilly's formulation in Lilly's containers. A compounded vial has a different formulation, is reconstituted by the patient, and is punctured repeatedly, so none of the 21-day room-temperature allowance carries over. For a compounded vial the rules are the pharmacy's label, the USP 28-day multiple-dose cap, refrigeration, no freezing and protection from light.

Sources: Zepbound prescribing information, 08/2026; Mounjaro prescribing information, 08/2026.

FAQ

How long does reconstituted tirzepatide last in the refrigerator?

Until the beyond-use date on the pharmacy label, kept at 36-46°F. USP <797> caps any multiple-dose sterile preparation at 28 days after first puncture or the assigned date, whichever is shorter, so some pharmacies label 21 days or less. Do not use the vial after that date; no published data describe potency beyond it.

Can I reconstitute tirzepatide with sterile water instead of bacteriostatic water?

No. Sterile water without preservative is single-use only. Bacteriostatic water contains 0.9% benzyl alcohol, which prevents bacterial growth over the 28-day use period. Using sterile water creates a contamination risk after the first puncture.

What concentration should I use for a 30mg vial?

3mL of bacteriostatic water (creating 10mg/mL) is the most common and easiest for dose math. Use 1.5mL (20mg/mL) if you're at high doses and want smaller injection volumes. Use 6mL (5mg/mL) if you have difficulty reading small unit counts on syringes.

Why is my reconstituted tirzepatide slightly yellow?

A faint straw-yellow tint is normal and comes from oxidation of trace impurities during storage. Deep yellow, orange, or brown indicates degradation and the vial should not be used.

Can I shake the vial to speed up dissolution?

No. Shaking creates foam and can denature the peptide. Let the powder dissolve passively over 3-5 minutes. Gentle side-to-side tilting after 2 minutes is acceptable if some powder remains.

What if I accidentally injected the water directly onto the powder and foam formed?

Wait 20-30 minutes for the foam to settle, then contact the pharmacy before using the vial; no published data quantify how much peptide is lost to foaming. For future reconstitutions, inject water slowly down the inside wall of the vial.

How do I know if my reconstituted tirzepatide is contaminated?

Cloudiness, particles, or a foul odor indicate contamination. Properly reconstituted tirzepatide is clear, colorless to faint yellow, and odorless. If you see cloudiness or particles, do not use the vial.

Can I store reconstituted tirzepatide at room temperature?

Follow the pharmacy label, and refrigerate between uses. The approved Zepbound and Mounjaro products allow up to 21 days at up to 30 C (labels revised 08/2026), but that testing does not cover compounded vials, and no published study measures reconstituted compounded tirzepatide at room temperature.

What size needle should I use for reconstitution?

An 18-gauge or 20-gauge needle. Smaller needles (25-gauge or thinner) create high back-pressure and increase the velocity of the water stream, which can cause foam. Save small-gauge needles for injection, not reconstitution.

How many doses are in a 30mg vial?

Depends on your dose. At 2.5mg per week, a 30mg vial contains 12 doses. At 5mg per week, 6 doses. At 7.5mg, 4 doses. At 10mg, 3 doses. At 15mg, 2 doses.

Can I reconstitute a vial that's been frozen?

No. Freezing disrupts the peptide structure. If a powder vial was frozen before reconstitution, the powder may not dissolve properly. If a reconstituted vial was frozen, the solution is unusable. Dispose of any frozen vials.

What if I added the wrong amount of bacteriostatic water?

You can still use the vial, but you must recalculate the concentration and unit count. Divide the total milligrams (30mg) by the volume you added to get the concentration, then use the formula (Dose in mg ÷ Concentration) × 100 = Units.

Why does my pharmacy's reconstitution protocol say to add 2mL but this guide says 3mL?

Different concentrations serve different needs. 2mL creates 15mg/mL, which reduces injection volume for patients at high doses. 3mL creates 10mg/mL, which has cleaner unit math. Both are correct. Follow your pharmacy's instructions unless you have a reason to customize.

Is the 28-day limit a tirzepatide stability result?

No. It is the USP <797> rule that a multiple-dose compounded sterile preparation may not be used beyond its assigned beyond-use date or 28 days after first puncture, whichever is shorter (revision official November 1, 2023). The pharmacy sets the actual date from its preparation category and testing, which can be shorter. No published study reports the potency of reconstituted compounded tirzepatide over time, so follow the label date.

How many adverse-event reports involve compounded tirzepatide?

More than 730 as of May 31, 2026, plus 990 for compounded semaglutide, according to FDA's page on unapproved GLP-1 drugs (content current as of September 1, 2026). FDA says compounders are not required to report, so the true number is likely higher, and it lists dosing errors by patients and clinicians among the causes. Its July 26, 2024 alert describes overdoses of 5 to 20 times the intended dose from confusing units with milliliters.

Can I use the 21-day room-temperature rule from the Zepbound label for my compounded vial?

No. The Zepbound and Mounjaro labels (revised 08/2026) allow a single-dose pen or vial up to 30 C for a total of 21 days, but that testing covers Lilly's formulation in Lilly's container. A compounded, patient-reconstituted, repeatedly punctured vial is a different product with no published stability data. Keep it refrigerated at 2 to 8 C, protect it from light, and follow the pharmacy's beyond-use date.

Related guides

• How to Reconstitute Semaglutide: The Complete Protocol for Compounded Peptide Mixing
• How to Reconstitute Tirzepatide 10mg: The Complete Mixing Protocol for Lyophilized Peptide Vials
• How to Reconstitute a 30 mg Vial of Tirzepatide: Step-by-Step Protocol for Safe Mixing
• Semaglutide Mixing Chart 10 mg: How to Reconstitute Compounded Semaglutide at Every Common Concentration
• How to Reconstitute Tirzepatide: A Step-by-Step Guide for Safe Mixing and Storage
• How to Reconstitute Tirzepatide at Home: A Step-by-Step Guide for Safe and Accurate Mixing
• Tool: reconstitution calculator

Sources

1. Florida Department of Health. USP General Chapter <797> sterile compounding inspection form (2022 revision, official November 1, 2023), August 2024. https://www.floridahealth.gov/wp-content/uploads/2025/08/SterileCompounding-Revision1USP7972022.August2024-1.pdf (Replaces an unverifiable Larsen 2023 citation, September 2026.)
2. Mississippi Board of Pharmacy. USP Compounding Beyond-Use Date Fact Sheet. https://www.mbp.ms.gov/sites/default/files/2023-03/USP_Compounding_BUD_Fact_Sheet.pdf (Replaces an unverifiable Chen 2024 citation, September 2026.)
3. United States Pharmacopeia. General Chapter <797> Pharmaceutical Compounding: Sterile Preparations, revised chapter published November 1, 2022, official November 1, 2023.
4. Eli Lilly and Company. Zepbound (tirzepatide) prescribing information, revised 08/2026, section 16 storage. https://pi.lilly.com/us/zepbound-uspi.pdf (Replaces an unverifiable Bakker 2022 citation, September 2026.)
5. U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products, July 26, 2024. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded (Replaces an unverifiable Patel 2024 citation, September 2026.)
6. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, content current as of September 1, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (Replaces an unverifiable Jorgensen 2021 citation, September 2026.)
7. Eli Lilly and Company. Mounjaro (tirzepatide) prescribing information, revised 08/2026, section 16 storage. https://pi.lilly.com/us/mounjaro-uspi.pdf
8. International Organization for Standardization. ISO 8537:2016 Sterile single-use syringes, with or without needle, for insulin. 2016.
9. Mahler HC et al. Protein aggregation: pathways, induction factors and analysis. Journal of Pharmaceutical Sciences. 2009.
10. Shire SJ et al. Challenges in the development of high protein concentration formulations. Journal of Pharmaceutical Sciences. 2004.
11. Cleland JL et al. The stability of recombinant human growth hormone in poly(lactic-co-glycolic acid) microspheres. Pharmaceutical Research. 1997.
12. Florida Department of Health. Sterile Compounding inspection form citing USP <797> (2022 revision, official November 1, 2023): multiple-dose CSP 28-day rule and Category 1, 2 and 3 beyond-use dates, August 2024. https://www.floridahealth.gov/wp-content/uploads/2025/08/SterileCompounding-Revision1USP7972022.August2024-1.pdf
13. Mississippi Board of Pharmacy. USP Compounding Beyond-Use Date Fact Sheet. https://www.mbp.ms.gov/sites/default/files/2023-03/USP_Compounding_BUD_Fact_Sheet.pdf
14. U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products, July 26, 2024. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
15. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, content current as of September 1, 2026 (adverse-event counts as of May 31, 2026; shortage resolution dates). https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
16. Eli Lilly and Company. Zepbound (tirzepatide) prescribing information, revised 08/2026, section 16. https://pi.lilly.com/us/zepbound-uspi.pdf
17. Eli Lilly and Company. Mounjaro (tirzepatide) prescribing information, revised 08/2026, section 16. https://pi.lilly.com/us/mounjaro-uspi.pdf
18. FormBlends. Compounded GLP-1 Price Index, data feed as of September 3, 2026. https://formblends.com/feeds/glp1-prices.json

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.